Remarks

Following entry of the above amendments, claims 1, 3-8, 13-20, 22, and 25-27 are pending. Claims 2, 9-12, 21, and 23-24 have been cancelled. Claims 25-26 are withdrawn. Claims 1, 6, 13, 19, 20, and 27 are amended to add clarify by rephrasing, correct punctuation and obvious errors, and focus on particular embodiments of the invention. Support for the amendments is found in the specification as originally filed. See, for example, page 4 lines 30-31, pages 49-83 and the Examples therein, and the claims as originally filed.

The Office Action states that claim 1 is rejected under 35 USC §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicants respectfully traverse the rejection. However, in an attempt to further prosecution, and comply with the earlier restriction requirement, Applicants amend claim 1. The rejection is now moot, and Applicants respectfully request withdrawal of the rejection.

The Office Action states that claims 9-11 are rejected under 35 USC §112, second paragraph, as lacking antecedent basis. Applicants have cancelled claims 9-11. Applicants respectfully request withdrawal of the rejection.

The Office Action states claims 1, 13, and 19 are objected to because of the informalities recited in the Office Action. Applicants have amended claims 1, 13, and 19 to overcome the objections. Applicants respectfully request reconsideration and withdrawal of the objections.

The Office Action states that claims 1, 9, 10, and 27 are objected to as containing non-elected subject matter. Applicants amend claims 1 and 27, and have cancelled claims 9-10. Applicants respectfully request reconsideration and withdrawal of the objections.

Applicants believe the present claims are in condition for allowance and such action is respectfully requested. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith.

Should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

If the Examiner has any outstanding issues with the pending claims, the Examiner is encouraged to telephone the undersigned at (919) 483-6334 for expeditious handling.

Respectfully submitted,

Jennifer L. Fox

Attorney for Applicants Registration No. 52,218

Date: January 16, 2007

GlaxoSmithKline

Corporate Intellectual Property Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709

Phone:

919-483-6334

Facsimile: 919-483-7988